Citations 1
Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio
Algeciras-Schimnich, Alicia, Reyes, Ramiro Eduardo Rea , Ashrafzadeh-Kian, Susan, Wilson, Rachel, MD, Miller, Johnson, D H, Botha, Hugo, Day, Gregory S., Graff-Radford, Jonathan, Ramanan, Vijay K., Jack, Clifford R., Johnson, Sterling C., Zetterberg, Henrik, Petersen, Ronald C., Bornhorst, Joshua A. , Algeciras‐Schimnich, Alicia , Bornhorst, Joshua , Figdore, Daniel J. , Ashrafzadeh‐Kian, Susan , Burkett, Brian J. , Botha, Hugo , McCarter, Stuart J. , Day, Gregory S. , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Jack, Clifford R. , Johnson, Sterling C. , Zetterberg, Henrik , Petersen, Ronald C.
JAMA Neurology | June 1, 2026 | Volume: 83 | Issue: 8 | Pages: 823
This cross-sectional study evaluates the performance of the US Food and Drug Administration–cleared phosphorylated tau 217 (p-tau217) to β-amyloid 42 ratio cut points used to detect amyloid pathology associated with Alzheimer disease.